Acute Toxicity Study of Zerumbone-Loaded Nanostructured Lipid Carrier on BALB/c Mice Model
Table 3
(a) Total RBC, Hb, PCV, and platelets count in mice treated with ZER, nanostructured lipid carrier (NLC), and zerumbone-loaded NLC. (b) Total and differential white blood cell count in mice treated with ZER, nanostructured lipid carrier (NLC), and zerumbone-loaded NLC.
(a)
Animal groups
Female
Platelets (×105/μL)
Male
Platelets (×105/μL)
Total RBC (×1012/L)
Hb (g/L)
PCV (L/L)
Total RBC (×1012/L)
Hb (g/L)
PCV (L/L)
Control
8.49 ± 0.7
138.3 ± 1.1
0.37 ± 0.05
6.3 ± 0.35
8.9 ± 0.17
140.3 ± 2.1
0.38 ± 0.75
6.5 ± 0.37
Vehicle
8.51 ± 0.11
140.0 ± 1.2
0.38 ± 0.04
6.6 ± 0.1
8.75 ± 0.15
141.0 ± 5.2
0.36 ± 0.35
6.55 ± 0.15
ZER (100 mg/kg)
8.34 ± 0.21
137.2 ± 2.3
0.35 ± 1.1
6.6 ± 0.11
8.35 ± 0.25
139.2 ± 0.9
0.36 ± 1.9
6.75 ± 0.21
ZER (200 mg/kg)
7.79 ± 0.32
138.4 ± 2.1
0.37 ± 2.2
6.4 ± 0.25
7.99 ± 0.35
139.5 ± 1.1
0.37 ± 2.5
6.46 ± 0.29
NLC (100 mg/kg)
8.10 ± 0.4
135.05 ± 1.7
0.37 ± 1.7
6.7 ± 0.31
8.5 ± 0.41
136.15 ± 1.5
0.38 ± 0.7
6.87 ± 0.55
NLC (200 mg/kg)
8.01 ± 0.34
136.6 ± 0.9
0.36 ± 0.5
6.1 ± 0.5
8.35 ± 0.33
135.1 ± 0.95
0.35 ± 0.9
6.95 ± 0.45
ZER-NLC (100 mg/kg)
8.22 ± 0.55
137.5 ± 1.5
0.35 ± 0.09
6.0 ± 0.07
8.29 ± 0.5
138.5 ± 1.01
0.36 ± 0.4
6.3 ± 0.09
ZER-NLC (200 mg/kg)
7.98 ± 0.06
138.44 ± 1.3
0.31 ± 0.31
6.25 ± 0.19
8.85 ± 0.75
139.02 ± 1.7
0.35 ± 0.11
6.45 ± 0.4
Values are mean ± SD () and have been analysed using post hoc comparison test one way ANOVA. Data revealed nonsignificant () difference in all hematological parameters after 14 days in all treated groups when compared to that of untreated control group.
(b)
()
TWBC (×103/μL)
Neutrophil (%)
Basophil (%)
Eosinophil (%)
Lymphocyte (%)
Monocyte (%)
Control
Female
2.75 ± 0.9
15 ± 0.15
0.00 ± 0.00
5 ± 0.5
70 ± 0.11
10 ± 0.75
Male
2.66 ± 0.15
16 ± 0.22
0.00 ± 0.00
3 ± 0.65
69 ± 0.17
12 ± 0.56
Vehicle
Female
2.55 ± 0.42
14 ± 0.7
0.00 ± 0.00
4 ± 0.13
70 ± 0.15
12 ± 0.5
Male
2.8 ± 0.5
15 ± 0.65
0.00 ± 0.00
3 ± 0.17
69 ± 0.7
13 ± 1.0
ZER (100 mg/kg)
Female
2.79 ± 0.13
14 ± 0.5
0.00 ± 0.00
5 ± 0.75
71 ± 0.91
10 ± 1.1
Male
2.8 ± 0.17
13 ± 0.23
0.00 ± 0.00
3 ± 0.45
73 ± 0.55
11 ± 1.1
ZER (200 mg/kg)
Female
2.79 ± 0.3
14 ± 0.43
0.00 ± 0.00
3 ± 0.15
75 ± 0.45
9 ± 0.45
Male
2.85 ± 0.32
12 ± 0.55
0.00 ± 0.00
5 ± 0.25
72 ± 0.67
11 ± 0.2
NLC (100 mg/kg)
Female
2.81 ± 1.4
15 ± 1.0
0.00 ± 0.00
4 ± 0.2
73 ± 0.95
8 ± 0.7
Male
2.83 ± 1.1
15 ± 0.67
0.00 ± 0.00
2 ± 0.3
72 ± 1.0
11 ± 0.9
NLC (200 mg/kg)
Female
2.9 ± 0.9
14 ± 0.45
0.00 ± 0.00
4 ± 0.9
71 ± 0.45
11 ± 1.0
Male
2.72 ± 0.81
15 ± 0.89
0.00 ± 0.00
3 ± 0.89
70 ± 0.25
12 ± 0.55
ZER-NLC (100 mg/kg)
Female
2.65 ± 0.55
16 ± 0.9
0.00 ± 0.00
3 ± 0.5
69 ± 0.6
12 ± 0.64
Male
2.89 ± 0.45
15 ± 1.2
0.00 ± 0.00
5 ± 0.75
69 ± 0.11
11 ± 0.79
ZER-NLC (200 mg/kg)
Female
2.63 ± 0.35
13 ± 0.5
0.00 ± 0.00
5 ± 0.61
70 ± 0.2
12 ± 0.85
Male
2.77 ± 0.85
15 ± 0.7
0.00 ± 0.00
4 ± 0.2
69 ± 0.35
12 ± 1.2
Treatment was performed for 14 days. Values are mean ± SD () and have been analyzed using post hoc comparison test one way ANOVA. Data revealed nonsignificant () difference in total and differential leucocyte count after 14 days in all treated groups when compared to that of untreated control group.
